Justin B. Echouffo-Tcheugui

Sep 26, 2023 | acpjournals.org | Michael Fang |Dan Wang |Justin B. Echouffo-Tcheugui |Elizabeth Selvin

Background: Adult-onset type 1 diabetes is frequently misdiagnosed as type 2 diabetes, leading to inappropriate care (1). Emerging data suggest that up to 62% of type 1 diabetes cases develop after age 20 years (2). However, prior studies have been done in selected clinical populations. Clarifying the burden of adult-onset type 1 diabetes in the general population may help reduce misdiagnosis.

Sep 19, 2023 | acpjournals.org | Michael Fang |Justin B. Echouffo-Tcheugui |Elizabeth Selvin

IN RESPONSE: Glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors may be important adjunct therapies for weight management in persons with T1DM. Our previous work has shown that approximately 5% of U.S. adults with T1DM receive a GLP-1 receptor agonist, and 3% receive an SGLT2 inhibitor (1). We believe at least 2 barriers may prevent greater uptake. The first barrier is safety.

Aug 8, 2023 | jamanetwork.com | Mayer B. Davidson |Charles R. Drew |Justin B. Echouffo-Tcheugui |Leigh Perreault

To the Editor A recent Review1 concluded that prediabetes is associated with an increased risk of cardiovascular disease events.

Aug 8, 2023 | jamanetwork.com | Sam Dagogo-Jack |Justin B. Echouffo-Tcheugui |Leigh Perreault |Linong Ji

In Reply In his Letter about our recent Review article,1 Dr Entezari-Maleki suggests that SGLT2 inhibitors be considered in the treatment of prediabetes while noting that no drug treatment has yet been approved by the FDA for people with prediabetes. Clearly, the glucosuric effect of SGLT2 inhibitors decreases blood glucose levels in people with hyperglycemia. Additionally, the weight loss induced by SGLT2 inhibitors would be beneficial in people with prediabetes who have overweight or obesity.